Testosterone 5-alpha-reductase: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Howard C. Berkowitz No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
In [[biology]], '''testosterone 5-alpha-reductase''' is an enzyme that | {{subpages}} | ||
{{TOC|right}} | |||
Inhibitors are [[finasteride]] and [[dutasteride]] are used to treat [[benign prostatic hypertrophy]]. Both of these medications are metaoblized by [[cytochrome P-450 CYP3A4]]. | In [[biology]], '''testosterone 5-alpha-reductase''' is an enzyme that produces dihydrotestosterone from [[testosterone]]. | ||
==Benign prostatic hypertrophy== | |||
Inhibitors are [[finasteride]] and [[dutasteride]] are used to treat [[benign prostatic hypertrophy]]. Both of these medications are metaoblized by [[cytochrome P-450 CYP3A4]].Dutasteride may better prevent acute urinary retention rates than finasteride effective according to a [[cohort study]].<ref name="pmid18611089">{{cite journal| author=Fenter TC, Davis EA, Shah MB, Lin PJ| title=Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years. | journal=Am J Manag Care | year= 2008 | volume= 14 | issue= 5 Suppl 2 | pages= S154-9 | pmid=18611089 | |||
Dutasteride may better prevent acute urinary retention rates than finasteride effective according to a [[cohort study]].<ref name="pmid18611089">{{cite journal| author=Fenter TC, Davis EA, Shah MB, Lin PJ| title=Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years. | journal=Am J Manag Care | year= 2008 | volume= 14 | issue= 5 Suppl 2 | pages= S154-9 | pmid=18611089 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=18611089 }} </ref> may better lower dihydrotestosterone.<ref name="pmid15126539">{{cite journal| author=Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S| title=Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. | journal=J Clin Endocrinol Metab | year= 2004 | volume= 89 | issue= 5 | pages= 2179-84 | pmid=15126539 | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=18611089 }} </ref> may better lower dihydrotestosterone.<ref name="pmid15126539">{{cite journal| author=Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S| title=Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. | journal=J Clin Endocrinol Metab | year= 2004 | volume= 89 | issue= 5 | pages= 2179-84 | pmid=15126539 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=15126539 }} </ref> It may also better reduce symptoms in preliminary trial.<ref name="pmid17364459">{{cite journal| author=Ravish IR, Nerli RB, Amarkhed SS| title=Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate. | journal=Arch Androl | year= 2007 Jan-Feb | volume= 53 | issue= 1 | pages= 17-20 | pmid=17364459 | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=15126539 }} </ref> It may also better reduce symptoms in preliminary trial.<ref name="pmid17364459">{{cite journal| author=Ravish IR, Nerli RB, Amarkhed SS| title=Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate. | journal=Arch Androl | year= 2007 Jan-Feb | volume= 53 | issue= 1 | pages= 17-20 | pmid=17364459 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=17364459 | doi=10.1080/01485010600888953 }} </ref> | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=17364459 | doi=10.1080/01485010600888953 }} </ref> | ||
==Developmental androgen disorders== | |||
Both testosterone 5-alpha-reductase deficiency and [[androgen receptor insensitivity]] involve this enzyme. The differential diagnosis can be difficult. <ref>{{citation | |||
| journal = Endocrine Abstracts | year = 2009 | volume =23 | page =P25 | |||
| title =Diagnostic Challenges in Androgen Insensitivity Syndrome & 5 Alpha Reductase Deficiency | |||
| author = E T George, S Alvi, N K Taylor & T Mushtaq | |||
| url = http://www.endocrine-abstracts.org/ea/0023/ea0023p25.htm | |||
}}</ref> | |||
==References== | |||
<references/> | <references/> | ||
Latest revision as of 21:14, 22 August 2010
In biology, testosterone 5-alpha-reductase is an enzyme that produces dihydrotestosterone from testosterone.
Benign prostatic hypertrophy
Inhibitors are finasteride and dutasteride are used to treat benign prostatic hypertrophy. Both of these medications are metaoblized by cytochrome P-450 CYP3A4.Dutasteride may better prevent acute urinary retention rates than finasteride effective according to a cohort study.[1] may better lower dihydrotestosterone.[2] It may also better reduce symptoms in preliminary trial.[3]
Developmental androgen disorders
Both testosterone 5-alpha-reductase deficiency and androgen receptor insensitivity involve this enzyme. The differential diagnosis can be difficult. [4]
References
- ↑ Fenter TC, Davis EA, Shah MB, Lin PJ (2008). "Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.". Am J Manag Care 14 (5 Suppl 2): S154-9. PMID 18611089.
- ↑ Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S (2004). "Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.". J Clin Endocrinol Metab 89 (5): 2179-84. PMID 15126539.
- ↑ Ravish IR, Nerli RB, Amarkhed SS (2007 Jan-Feb). "Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.". Arch Androl 53 (1): 17-20. DOI:10.1080/01485010600888953. PMID 17364459. Research Blogging.
- ↑ E T George, S Alvi, N K Taylor & T Mushtaq (2009), "Diagnostic Challenges in Androgen Insensitivity Syndrome & 5 Alpha Reductase Deficiency", Endocrine Abstracts 23: P25